Ionis Pharmaceuticals IncIONS

Why is Ionis Pharmaceuticals (IONS) moving?

Q3 202624 Jun – 29 Sep 2026

▲2▼2

Ionis Q3: New Drug Launches and Partner Wins Offset by Trial Failures

Tryngolza Approval and Self-Launch Ionis won FDA approval for Tryngolza to treat severely high triglycerides and launched it on its own, a first for the company. This adds a new revenue stream and shows it can sell drugs directly.
This is a major new product launch that directly boosts revenue potential.
Zanvastro Approval and Partner Successes FDA approved Zanvastro for Alexander disease, and partner drugs sefaxersen and ulefnersen met key Phase 3 goals. These validate Ionis' RNA technology and bring milestone payments and royalties.
These approvals and trial wins confirm the platform and add near-term cash.
Multiple Clinical Trial Failures Several Phase 3 and Phase 2 trials failed, including eplontersen, Wainua, Roche's Huntington's programs, and diranersen. These setbacks raise doubts about the pipeline and future revenue.
Trial failures directly hurt investor confidence and future prospects.
Fraud Investigations and Competitive Pressures Securities fraud investigations into Wainua disclosures and competition from Arrowhead's plozasiran weighed on the stock. Also, Novartis' pelacarsen failed a Phase 3 heart trial, casting doubt on RNA silencer technology.
Legal and competitive risks add uncertainty and could slow growth.

September 202628 Aug – 29 Sep 2026

▲3▼1

Ionis pipeline wins offset partner trial failure

FDA approves Zanvastro for Alexander disease The FDA approved Zanvastro (zilganersen), the first-ever treatment for Alexander disease, validating Ionis' RNA-targeting platform and adding a new revenue stream. This is a major milestone for the company.
This is a new approval that directly boosts Ionis' revenue potential and validates its technology.
Partner Roche's sefaxersen meets Phase 3 goal Partner Roche's sefaxersen met its Phase 3 goal in IgA nephropathy, earning Ionis milestones and royalties. This success demonstrates the broad potential of Ionis' RNA-targeting platform beyond its own drugs.
This is a new positive clinical result that brings financial benefits and platform validation.
Ulefnersen succeeds in FUS-ALS Ulefnersen succeeded in FUS-ALS, another pipeline win that earns milestones and royalties. This further supports the platform's versatility and potential in different diseases.
This is a new clinical success that adds to the positive momentum and financial upside.
Novartis' pelacarsen fails Phase 3 heart trial Partner Novartis' pelacarsen failed its Phase 3 heart trial, removing a potential blockbuster and briefly dropping shares 6.18%. Analysts saw limited financial impact, but it raised doubts about RNA silencer technology.
This is a new negative event that weighed on sentiment and highlights risks in the pipeline.

Latest23 Sep – 29 Sep 2026

▲2

Ionis turns the corner: two Phase 3 wins revive pipeline after setbacks

Sefaxersen hits Phase 3 goal in IgA nephropathy Partner Roche reported that sefaxersen met its main Phase 3 goal in IgA nephropathy, a kidney disease, with strong protein reductions and no new safety issues. Ionis gets milestone payments and royalties, and the win shows its RNA technology works in a large market.
This is a new clinical win that directly lifts confidence in Ionis's platform and future royalty revenue.
Ulefnersen succeeds in rare FUS-ALS Ionis and Otsuka said ulefnersen met its main late-stage goal in FUS-ALS, a rare inherited form of ALS, improving function and survival. No approved treatment targets this genetic cause, and they will seek accelerated approval. Ionis earns milestones and royalties.
A second new Phase 3 success in a different disease area broadens the pipeline and adds another potential revenue stream.

28 Aug – 14 Sep 2026

▼3▲1

FDA approval for Zanvastro offset by pelacarsen trial failure

FDA approves Zanvastro, first Alexander disease treatment The FDA approved Ionis' Zanvastro (zilganersen) as the first-ever treatment for Alexander disease, a rare neurological condition. This is a new commercial product and validates Ionis' RNA-targeting platform, giving the company a new revenue stream and lifting investor confidence.
This is a major new approval that directly boosts Ionis' revenue prospects and pipeline credibility.
Partner Novartis' pelacarsen fails Phase 3 heart trial Novartis' pelacarsen, discovered by Ionis and licensed to Novartis, failed its Phase 3 Lp(a)HORIZON trial. It lowered Lp(a) but did not reduce cardiovascular events. Ionis shares fell 6.18% after hours. This is a setback for a partnered asset and raises doubts about the Lp(a) approach.
This is the main negative event of the period, directly hitting Ionis' pipeline and stock price.
Analysts see limited financial impact from pelacarsen failure BofA and Citi analysts said the pelacarsen failure has low-single-digit downside for Ionis and should not affect 2026 guidance. Citi maintains a Buy rating and $100 target. This suggests the market may be overreacting, but the failure still removes a potential blockbuster.
It provides context on the financial materiality of the pelacarsen failure, helping investors gauge the real impact.
Wainua Phase 3 failure in ATTR-CM adds to RNA silencer doubts Full Phase 3 data for Wainua (with AstraZeneca) failed to meet its primary goal in ATTR-CM. An analyst said oral stabilizers may be superior to subcutaneous silencers. This hurts Alnylam and has negative read-through for Ionis' RNA silencer technology.
It is a separate negative trial result that questions the broader RNA silencer approach Ionis uses.

July 202624 Jun – 30 Jul 2026

▲2▼2

Ionis mixed: Tryngolza approval offset by trial failures

Tryngolza FDA approval and self-launch The FDA approved Tryngolza for severe high triglycerides, cutting levels up to 72%, and Ionis began selling it itself in July. This opens a new revenue stream and shows the company can launch its own drug.
A major new product approval and launch is a key positive force for the stock.
Q2 earnings beat and guidance reaffirmed Ionis reported better-than-expected second-quarter results and kept its full-year guidance unchanged. This reassured investors about the company's financial health despite recent setbacks.
Earnings beat and reaffirmed guidance support investor confidence.
Multiple Phase 3 and Phase 2 trial failures Eplontersen and Wainua failed Phase 3 heart trials, Roche dropped two partnered Huntington's programs, and diranersen missed its Phase 2 Alzheimer's endpoint. These failures erased major hoped-for revenue and sent shares down sharply.
Clinical failures are the main negative driver, wiping out key pipeline value.
Legal investigations and competitive threat Securities fraud investigations into Wainua disclosures add legal uncertainty. Meanwhile, Arrowhead's rival plozasiran showed stronger triglyceride data, threatening future market share for Tryngolza.
Legal risk and competitive pressure weigh on the stock and future sales.

18 Jul – 30 Jul 2026

▲2▼1

Ionis beats Q2, but rival lipid data and legal probes weigh

Q2 earnings beat and guidance reaffirmed Ionis reported a smaller-than-expected loss and higher revenue, and kept its 2026 sales and loss forecasts unchanged. That tells investors the core business is on track, which supports the stock even after recent trial setbacks.
This is the period's main new positive fundamental event and directly counters the negative narrative.
Arrowhead's rival lipid drug succeeds, pressuring Ionis Arrowhead's plozasiran cut triglycerides by about 80% in a late-stage trial, beating Ionis's competing olezarsen. If approved, it could take market share in the same severe high-triglyceride market, making Ionis's future sales outlook less certain.
This is a new competitive threat that directly affects Ionis's key growth market.
ARK ETF buys $15.3 million of Ionis shares Cathie Wood's ARK fund bought $15.3 million of Ionis stock after the trial-driven selloff. A well-known investor stepping in can steady sentiment and signal that some see the drop as overdone, though it does not change the company's fundamentals.
This is a new capital-flow signal that helps explain the stock's stabilization after the crash.

25 Jun – 14 Jul 2026

▼3▲1

Ionis hit by trial failures and legal probes, but pipeline and licensing advance

Wainua heart trial failure and Roche's Huntington's exit Ionis and AstraZeneca's Wainua failed a Phase 3 heart trial, and Roche scrapped two partnered Huntington's programs. Shares fell about 29% in two days, wiping out a large expected revenue source and shaking confidence in the pipeline.
This is the biggest new negative event, directly causing a sharp price drop and removing a major future revenue driver.
Securities fraud investigations launched Law firms Hagens Berman and Pomerantz are investigating whether Ionis misled investors about the Wainua trial's design and prospects. Legal uncertainty can pressure the stock and distract management, even if no charges are filed.
New legal probes add a fresh layer of risk and uncertainty that can weigh on the stock price.
Alzheimer's drug misses primary endpoint in Phase 2 Biogen and Ionis's diranersen missed its main goal in a mid-stage Alzheimer's trial, though it showed some benefit on secondary measures. The miss is a setback for a partnered pipeline asset, but Phase 3 plans continue.
This is a new clinical disappointment that adds to negative sentiment around Ionis's partnered programs.
Zilganersen licensed to Recordati and Angelman enrollment complete Ionis licensed zilganersen for Alexander disease outside the U.S. to Recordati for $30 million upfront plus royalties, and completed enrollment in the pivotal Phase 3 trial for its Angelman syndrome drug. These show pipeline progress and bring in cash.
These are new positive developments that highlight Ionis's pipeline strength and near-term revenue potential, offering a counterweight to the negative news.

24 Jun – 9 Jul 2026

▼2▲1

Ionis wins first big approval but heart drug trial fails

FDA approves Tryngolza for severe high triglycerides The FDA approved Tryngolza as the first treatment for severe hypertriglyceridemia, a condition affecting nearly 3 million Americans. It cuts triglycerides up to 72% and pancreatitis risk up to 91%. Ionis will launch it itself in July, opening a large new market and potential revenue stream.
This is a major new approval that expands Ionis's commercial opportunity and drives the stock up.
Eplontersen fails Phase 3 ATTR-CM trial Ionis and AstraZeneca's eplontersen missed its primary endpoint in the CARDIO-TTRansform trial for ATTR-CM, a heart condition. The drug failed to reduce cardiovascular deaths or events. This removes a large expected revenue opportunity and caused Ionis shares to drop sharply.
This is a major clinical failure that directly hurts Ionis's growth prospects and stock price.
Ionis stock plunges on eplontersen news Following the trial failure, Ionis shares fell as much as 19% intraday. The setback also lifted rival ATTR-CM drugs from Alnylam and BridgeBio, highlighting lost competitive ground. The full data will be presented in August, but the primary endpoint miss is a clear negative.
This shows the immediate market reaction and competitive impact of the trial failure.